Xin Lang Cai Jing·2026-02-25 05:57Group 1 - The core viewpoint of the news is that Spring Medical has shown significant financial performance with a notable increase in revenue and net profit, indicating strong growth potential in the orthopedic medical device sector [2][3]. - As of February 24, Spring Medical's stock price increased by 0.58%, with a trading volume of 34.10 million yuan, and a net financing purchase of 11.70 million yuan, reflecting active investor interest [1]. - The company's financing balance reached 70.30 million yuan, accounting for 1.09% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of investor engagement [1]. Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prostheses and spinal implants, which are exported to various regions worldwide [2]. - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, which is a 213.21% increase compared to the previous year [2]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years, indicating a commitment to returning value to shareholders [3].